Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.56USD
23 Apr 2018
Change (% chg)

$0.05 (+1.99%)
Prev Close
$2.51
Open
$2.51
Day's High
$2.58
Day's Low
$2.46
Volume
78,326
Avg. Vol
177,383
52-wk High
$4.51
52-wk Low
$1.64

Select another date:

Thu, Apr 19 2018

BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis

* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:

BRIEF-Catalyst Pharma Submits NDA For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME

BRIEF-Catalyst Pharmaceuticals Announces Q4 Gaap Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Pharmaceuticals Announces Plans To Resubmit New Drug Application For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES PLANS TO RESUBMIT NEW DRUG APPLICATION FOR FIRDAPSE®

BRIEF-Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma

* GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING Source text for Eikon: (http://bit.ly/2jaVqTo) Further company coverage:

BRIEF-Catalyst Pharmaceuticals Inc Prices Previously Announced Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. PRICES PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Pharma Announces Proposed Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME

BRIEF-Catalyst Pharmaceuticals ‍announces phase 2 study of Firdapse

* Announces phase 2 study of Firdapse in ambulatory patients with spinal muscular atrophy​

BRIEF-Catalyst Pharmaceuticals posts Q3 loss per share $0.05

* Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update

Select another date: